For example, in recurrent cervical cancer, pembrolizumab was observed to have antitumor activity in patients with PD-L1 positive tumors (combined positive score, ≥1), but not in PD-L1 negative tumors (54), and cemiplimab exhibited higher ORR in patients with PD-L1 positive expression than in patients with PD-L1 low expression (55). Here, CD274 is linked to cervical cancer.